Key facts
| Item | Details |
|---|---|
| Active ingredient | Tirzepatide (GIP and GLP-1 receptor agonist) |
| Maker | Eli Lilly |
| Forms | Weekly injection: single-dose vials and KwikPen; doses 2.5–15 mg |
| FDA-approved uses | Chronic weight management in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity |
| Self-pay price (LillyDirect) | Vials $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) per month; KwikPen about $299–$449 by dose |
FDA approval timeline
| Date | Milestone |
|---|---|
| November 2023 | Approved for chronic weight management |
| December 2024 | Approved for obstructive sleep apnea in adults with obesity |
| February 2026 | KwikPen available to self-pay patients via LillyDirect |
| July 2026 | Zepbound KwikPen included in the Medicare GLP-1 Bridge |
What the trials found
In SURMOUNT-1, adults on the highest dose lost about 21% of body weight on average over 72 weeks. In the head-to-head SURMOUNT-5 trial, tirzepatide produced about 20% average weight loss compared with about 14% for semaglutide. These are trial averages, not a promise of individual results.
Side effects and warnings
The most common side effects in trials were nausea, diarrhea, vomiting and constipation, mostly while the dose was increasing. The label carries a boxed warning about thyroid C-cell tumors seen in rodents. See our side effects guide.
Where to get Zepbound
Zepbound needs a prescription. Telehealth programs we review that list it:
| Provider | Typical price | Our score |
|---|---|---|
| Ro Body Program | From ~$448/mo all-in (Wegovy pill) | Our score: 9.3/10 |
| LillyDirect | Zepbound vials ~$299–$449/mo; Foundayo from $149/mo | Our score: 9.1/10 |
| Found | From ~$289/mo | Our score: 8.6/10 |
| BiltRx | Compounded semaglutide from $81/mo; tirzepatide from $129/mo (+ consult and shipping) | Our score: 8.4/10 |
| WeightWatchers Clinic | ~$373/mo after intro month | Our score: 8.2/10 |
Compare prices in our tracker → · Estimate your monthly cost →
Compounded GLP-1s are not FDA-approved. They are not equivalent to Zepbound. Which medication, if any, is suitable is decided by a licensed clinician.
FAQ
What is Zepbound?
Zepbound is a brand-name prescription medicine made by Eli Lilly. Its active ingredient is tirzepatide.
Is compounded tirzepatide the same as Zepbound?
No. Compounded tirzepatide is not FDA-approved and is not equivalent to Zepbound. The FDA does not review compounded drugs for safety, effectiveness or quality.
How do I get Zepbound?
Zepbound requires a prescription from a licensed clinician, who decides whether it is suitable for you. Prescriptions can be filled at retail pharmacies, through telehealth programs or at the manufacturer's self-pay pharmacy.
Related guides
- Zepbound vials vs pens: How the two Zepbound formats differ in price, how you inject them and whether insurance applies.
- Semaglutide vs tirzepatide: How Wegovy and Zepbound differ in how they work, results, side effects and price.
- LillyDirect vs NovoCare: How Eli Lilly's and Novo Nordisk's self-pay pharmacies work, what they charge by dose and what you need to order.
- Stopping a GLP-1: What trials found about weight and health markers after people stopped semaglutide or tirzepatide.
Sources
- Zepbound prescribing information
- Jastreboff et al., SURMOUNT-1, NEJM 2022
- SURMOUNT-5 summary (American College of Cardiology)
- WebMD: FDA approves Zepbound for sleep apnea
- LillyDirect self-pay options
GLP1Rated is for general information only and is not medical advice. GLP-1 medications are prescription drugs with real risks and side effects. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.